Enhanced Protective Immunity Against SARS-CoV-2 Elicited by a VSV Vector Expressing a Chimeric Spike Protein

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2021 Nov 11

PMID 34759261

Citations 19

Authors

Hongyue Li

Yuhang Zhang

Dong Li

Yong-Qiang Deng

Hongde Xu

Chaoyue Zhao

Jiandong Liu

Dan Wen

Jianguo Zhao

Yongchun Li

Yong Wu

Shujun Liu

Jiankai Liu

Junfeng Hao

Fei Yuan

Shuguang Duo

Cheng-Feng Qin

Aihua Zheng

Affiliations

Soon will be listed here.

Abstract

SARS-CoV-2 and SARS-CoV are genetically related coronavirus and share the same cellular receptor ACE2. By replacing the VSV glycoprotein with the spikes (S) of SARS-CoV-2 and SARS-CoV, we generated two replication-competent recombinant viruses, rVSV-SARS-CoV-2 and rVSV-SARS-CoV. Using wild-type and human ACE2 (hACE2) knock-in mouse models, we found a single dose of rVSV-SARS-CoV could elicit strong humoral immune response via both intranasal (i.n.) and intramuscular (i.m.) routes. Despite the high genetic similarity between SARS-CoV-2 and SARS-CoV, no obvious cross-neutralizing activity was observed in the immunized mice sera. In macaques, neutralizing antibody (NAb) titers induced by one i.n. dose of rVSV-SARS-CoV-2 were eight-fold higher than those by a single i.m. dose. Thus, our data indicates that rVSV-SARS-CoV-2 might be suitable for i.n. administration instead of the traditional i.m. immunization in human. Because rVSV-SARS-CoV elicited significantly stronger NAb responses than rVSV-SARS-CoV-2 in a route-independent manner, we generated a chimeric antigen by replacing the receptor binding domain (RBD) of SARS-CoV S with that from the SARS-CoV-2. rVSV expressing the chimera (rVSV-SARS-CoV/2-RBD) induced significantly increased NAbs against SARS-CoV-2 in mice and macaques than rVSV-SARS-CoV-2, with a safe Th1-biased response. Serum immunized with rVSV-SARS-CoV/2-RBD showed no cross-reactivity with SARS-CoV. hACE2 mice receiving a single i.m. dose of either rVSV-SARS-CoV-2 or rVSV-SARS-CoV/2-RBD were fully protected against SARS-CoV-2 challenge without obvious lesions in the lungs. Our results suggest that transplantation of SARS-CoV-2 RBD into the S protein of SARS-CoV might be a promising antigen design for COVID-19 vaccines.

Citing Articles

N6-methyladenosine RNA modification promotes Severe Fever with Thrombocytopenia Syndrome Virus infection.

Chen Z, Zhang J, Wang J, Tong H, Pan W, Ma F PLoS Pathog. 2024; 20(11):e1012725.

PMID: 39585899 PMC: 11627400. DOI: 10.1371/journal.ppat.1012725.

Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.

Wang S, Li W, Wang Z, Yang W, Li E, Xia X Signal Transduct Target Ther. 2024; 9(1):223.

PMID: 39256346 PMC: 11412324. DOI: 10.1038/s41392-024-01917-x.

Bacteriophage T4 as a Protein-Based, Adjuvant- and Needle-Free, Mucosal Pandemic Vaccine Design Platform.

Zhu J, Tao P, Chopra A, Rao V Annu Rev Virol. 2024; 11(1):395-420.

PMID: 38768614 PMC: 11690488. DOI: 10.1146/annurev-virology-111821-111145.

Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSV) in golden syrian hamster.

Ke Y, Zhang E, Guo J, Zhang X, Wang L, Chen D Acta Pharm Sin B. 2023; 13(12):4856-4874.

PMID: 38045049 PMC: 10692390. DOI: 10.1016/j.apsb.2023.08.023.

Recombinant Lactococcus lactis Expressing Human LL-37 Prevents Deaths from Viral Infections in Piglets and Chicken.

Zhang H, Dong M, Xu H, Li H, Zheng A, Sun G Probiotics Antimicrob Proteins. 2023; 16(6):2150-2160.

PMID: 37743432 DOI: 10.1007/s12602-023-10155-6.

References

Zhu Y, Yu D, Han Y, Yan H, Chong H, Ren L . Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. Sci Adv. 2020; 6(45). PMC: 7673700. DOI: 10.1126/sciadv.abc9999. View

Hoffmann M, Kleine-Weber H, Pohlmann S . A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell. 2020; 78(4):779-784.e5. PMC: 7194065. DOI: 10.1016/j.molcel.2020.04.022. View

Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M . A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020; 369(6504):650-655. PMC: 7319273. DOI: 10.1126/science.abc6952. View

Walls A, Park Y, Tortorici M, Wall A, McGuire A, Veesler D . Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 183(6):1735. PMC: 7833104. DOI: 10.1016/j.cell.2020.11.032. View

Cao W, Liu W, Zhang P, Zhang F, Richardus J . Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007; 357(11):1162-3. DOI: 10.1056/NEJMc070348. View

Roberts A, Buonocore L, Price R, Forman J, Rose J . Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol. 1999; 73(5):3723-32. PMC: 104148. DOI: 10.1128/JVI.73.5.3723-3732.1999. View

Henao-Restrepo A, Longini I, Egger M, Dean N, Edmunds W, Camacho A . Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015; 386(9996):857-66. DOI: 10.1016/S0140-6736(15)61117-5. View

Li H, Zhao C, Zhang Y, Yuan F, Zhang Q, Shi X . Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays. Emerg Microbes Infect. 2020; 9(1):2269-2277. PMC: 7594855. DOI: 10.1080/22221751.2020.1830715. View

Dong F, Li D, Wen D, Li S, Zhao C, Qi Y . Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus. NPJ Vaccines. 2019; 4:5. PMC: 6347601. DOI: 10.1038/s41541-018-0096-y. View

10.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

11.

Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

12.

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

13.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

14.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

15.

Pallesen J, Wang N, Corbett K, Wrapp D, Kirchdoerfer R, Turner H . Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017; 114(35):E7348-E7357. PMC: 5584442. DOI: 10.1073/pnas.1707304114. View

16.

Mo H, Zeng G, Ren X, Li H, Ke C, Tan Y . Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. Respirology. 2006; 11(1):49-53. PMC: 7192223. DOI: 10.1111/j.1440-1843.2006.00783.x. View

17.

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

18.

Liu Y, Hu G, Wang Y, Ren W, Zhao X, Ji F . Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2. Proc Natl Acad Sci U S A. 2021; 118(12). PMC: 8000431. DOI: 10.1073/pnas.2025373118. View

19.

Lee W, Wheatley A, Kent S, DeKosky B . Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020; 5(10):1185-1191. DOI: 10.1038/s41564-020-00789-5. View

20.

Henao-Restrepo A, Camacho A, Longini I, Watson C, Edmunds W, Egger M . Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2016; 389(10068):505-518. PMC: 5364328. DOI: 10.1016/S0140-6736(16)32621-6. View